Your one- stop shop, from radiolabeling and preclinical biodistribution studies to IND-enabling dosimetry and efficacy studies, Perceptive Discovery delivers precise, translatable multi-modality imaging data to accelerate your oncology and radiopharmaceutical programs.
Perceptive Discovery delivers advanced preclinical oncology imaging and radiopharmaceutical development services to support therapeutic programs from discovery through early clinical development. Our cross-disciplinary team of radiochemists, imaging scientists, and oncology pharmacologists, work collaboratively to de-risk discovery and early-phase development by visualizing images of anti-tumor efficacy, target engagement, pharmacokinetics, dosimetry and therapeutic biodistribution in clinically relevant tumor models.
With deep expertise in radiopharmaceuticals and radioligand therapy (RLT), we help clients design and validate custom-labeled agents, quantify tumor uptake, and predict human dose and safety profiles—accelerating the path from concept to clinic.
Support your RLT program with comprehensive imaging and dosimetry services. We design studies using diagnostic/therapeutic isotope pairs (e.g., Zr-89/Lu-177 or Pb-203/Pb-212) to evaluate biodistribution, tumor targeting, and normal tissue dose.
Design and validate companion imaging agents for patient stratification and dose prediction using isotopes like F-18, Ga-68, Cu-64, and Zr-89.
Visualize CAR-T, oncolytic virus, and engineered cell biodistribution in real time using bioluminescence and advanced radiolabeling.
Quantify efficacy in disease-relevant models to increase translational confidence and guide candidate selection.
Gain fast, actionable insights through automated data processing pipelines—supporting segmentation, dosimetry, PK/PD evaluation, and therapeutic response modeling.
Learn more about our radiochemistry services
Perceptive offers a broad portfolio of in vivo oncology imaging modalities. which include: PET, SPECT, MRI, CT, bioluminescence (BLI), fluorescence (FLI), and cryofluorescence tomography (CFT). These are in order to track tumor growth, evaluate biodistribution, measure target engagement, and assess therapeutic efficacy in preclinical models.
We support a range of tumor model systems, including syngeneic, cell derived xenograft (CDX), and orthotopic tumor models, enabling disease relevant oncology research and enhancing translational value for clinical applications.
Our team provides radiochemistry, imaging, biodistribution, and dosimetry support for radiopharmaceutical therapy programs. We work with a wide variety of therapeutic isotopes, including alpha and beta emitters, and can support theranostic pairs to accelerate translational oncology research.
We have extensive experience supporting radiopharmaceutical therapies, antibody drug conjugates (ADCs), CAR-T cell therapies, oncolytic viruses, and small molecule therapeutics in oncology imaging studies, ensuring robust data packages across modalities.
By combining multi modality imaging, harmonized workflows, advanced quantitative analysis, and disease relevant tumor models, Perceptive generates pharma ready data that de risk discovery programs and strengthen IND-enabling oncology packages.
Reach out today and one of our solution experts will be in touch to learn about your specific needs.
"*" indicates required fields
